Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

NCT05026983 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Clinical Stage IV Cutaneous Melanoma AJCC v8
Metastatic Melanoma
Pathologic Stage IV Cutaneous Melanoma AJCC v8

Interventions

DRUG: Binimetinib
DRUG: Encorafenib
OTHER: Questionnaire Administration

Sponsor

M.D. Anderson Cancer Center